- Forbes•9 hours ago
The FDA has approved at least two drugs recently that critics and some agency staff lacked adequate evidence of safety and effectiveness. As a result, will the agency become more forceful in urging drug makers to conduct better studies?
- Forbes•15 hours ago
Let’s not use the eteplirsen approval as a way to lobby for new ways to put constraints on the biopharmaceutical industry.
After meeting with Sarepta Therapeutics' (SRPT) management, Leerink's Joseph Schwartz and Dae Gon Ha offer an update on the company but can't help including a dig at the company's Duchenne muscular dystrophy treatment, which was recently approved by the FDA. From their note: Setting aside the controversy around the questionable data and basis for approval, the FDA’s blessing has shifted investors’ theses on the stock, which has now become a commercial execution and potential takeover story. Of course, there's always the question of who will pay for Sarepta's pricey drug: Despite Anthem’s (ANTM)) announcement that they will deny coverage, Sarepta still believes payors (including Anthem) will eventually cover Exondys 51.
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||42.65 x 100|
|Ask||44.68 x 500|
|Day's Range||44.36 - 46.54|
|52wk Range||8.00 - 63.73|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.31|
|Avg Vol (3m)||4,087,323|
|Dividend & Yield||N/A (N/A)|